Literature DB >> 3069478

Pharmacokinetics and tissue concentrations of ceftazidime in burn patients.

R A Walstad1, L Aanderud, E Thurmann-Nielsen.   

Abstract

The pharmacokinetics and tissue concentrations of ceftazidime have been investigated in 8 patients with severe burns (20-80% of body surface area) undergoing skin transplantation 2 to 21 days after injury. Two prophylactic doses of ceftazidime were administered as 1 g i.v. bolus injections with an 8 h interval. Blood, urine, burn blister fluid and tissue were frequently sampled and drug concentrations were analyzed by HPLC. The kinetics of ceftazidime was the same after each dose. In these patients the pharmacokinetics of ceftazidime was greatly altered from that in other patients and there was much interindividual variation. The mean ceftazidime elimination half-life, apparent volume of distribution and total clearance were: 2.7 h, 30.91 (0.38 1.kg-1) and 139 ml.min-1, respectively. A linear correlation was found between creatinine clearance and the renal clearance of the ceftazidime, the mean values being 108 and 95 ml.min-1, respectively. No correlation was found between creatinine clearance and the total clearance of ceftazidime. The mean percentage urine recovery was 69% of the dose. Tissue and burn blister fluid concentrations were above the MIC, and ranged from 40.0 to 3.1 mg.kg-1. A substantial increase in the apparent volume of distribution and non-renal clearance of ceftazidime was observed, probably due to increased capillary permeability and drug loss through the wound surface replacement of prior to surgery and subsequently to lost and blood fluid.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3069478     DOI: 10.1007/bf00558251

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  19 in total

Review 1.  Fluid volume and electrolyte changes of the early postburn period.

Authors:  C R Baxter
Journal:  Clin Plast Surg       Date:  1974-10       Impact factor: 2.017

2.  Studies on renal function in burns. I. Renal osmolal regulation, glomerular filtration rate and plasma solute composition related to age, burned surface area and mortality probability.

Authors:  J Eklund; P O Granberg; S O Liljedahl
Journal:  Acta Chir Scand       Date:  1970

3.  Biliary elimination of ceftazidime.

Authors:  J M Brogard; F Jehl; D Pâris-Bockel; J F Blicklé; M Adloff; H Monteil
Journal:  J Antimicrob Chemother       Date:  1987-05       Impact factor: 5.790

4.  Pharmacokinetics and tissue penetration of ceftazidime: studies on lymph, aqueous humour, skin blister, cerebrospinal and pleural fluid.

Authors:  R A Walstad; K B Hellum; S Blika; L G Dale; T Fredriksen; K I Myhre; G R Spencer
Journal:  J Antimicrob Chemother       Date:  1983-07       Impact factor: 5.790

5.  Renal function and renal failure in badly burned children.

Authors:  J S Cameron; C M Miller-Jones
Journal:  Br J Surg       Date:  1967-02       Impact factor: 6.939

6.  The pharmacokinetics of ceftazidime in patients with impaired renal function and concurrent frusemide therapy.

Authors:  R A Walstad; K Dahl; K B Hellum; E Thurmann-Nielsen
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

7.  Ceftazidime and renal function.

Authors:  K Alestig; B Trollfors; R Andersson; L Olaison; M Suurküla; S R Norrby
Journal:  J Antimicrob Chemother       Date:  1984-02       Impact factor: 5.790

8.  Pathophysiology of the burn wound.

Authors:  G Arturson
Journal:  Ann Chir Gynaecol       Date:  1980

9.  Increased dosage requirements of gentamicin in burn patients.

Authors:  D E Zaske; R J Sawchuk; D N Gerding; R G Strate
Journal:  J Trauma       Date:  1976-10

10.  Ceftazidime, a pseudomonas-active cephalosporin: in-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility tests.

Authors:  R N Jones; A L Barry; C Thornsberry; E H Gerlach; P C Fuchs; T L Gavan; H M Sommers
Journal:  J Antimicrob Chemother       Date:  1981-09       Impact factor: 5.790

View more
  15 in total

1.  Population pharmacokinetics of ceftazidime in burn patients.

Authors:  Eric Dailly; Michel Pannier; Pascale Jolliet; Michel Bourin
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

2.  Levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury.

Authors:  Tyree H Kiser; Dorie W Hoody; Marilee D Obritsch; Colleen O Wegzyn; Paulus C Bauling; Douglas N Fish
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

3.  Fluconazole pharmacokinetics in burn patients.

Authors:  B A Boucher; S R King; H L Wandschneider; W L Hickerson; S D Hanes; V L Herring; T W Canada; M M Hess
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

Review 4.  Pathophysiology and pharmacokinetics following burn injury.

Authors:  P L Bonate
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

5.  Pharmacokinetics of cefepime in patients with thermal burn injury.

Authors:  C R Bonapace; R L White; L V Friedrich; E D Norcross; J A Bosso
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

Review 6.  Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability.

Authors:  Federico Pea; Pierluigi Viale; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

7.  Clinical pharmacokinetics of piperacillin-tazobactam combination in patients with major burns and signs of infection.

Authors:  P Bourget; A Lesne-Hulin; R Le Reveillé; H Le Bever; H Carsin
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

8.  Tissue accumulation of cephalothin in burns: a comparative study by microdialysis of subcutaneous interstitial fluid cephalothin concentrations in burn patients and healthy volunteers.

Authors:  Andrew J Dalley; Jeffrey Lipman; Renae Deans; Bala Venkatesh; Michael Rudd; Michael S Roberts; Sheree E Cross
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

9.  The bacteriological profile of the burned patients in the center of burns in CHU Mohamed VI Marrakech (about 123 cases).

Authors:  Yassine Benchamkha; Ouafaa Dhaidah; Adil Dahazze; Quaboul Meriem; Moulay Driss Elamrani; Salwa Ettalbi
Journal:  Int J Burns Trauma       Date:  2017-10-25

Review 10.  Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients.

Authors:  Benoit Blanchet; Vincent Jullien; Christophe Vinsonneau; Michel Tod
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.